An expert panel will convene on Wednesday to study clinical trial data on Brilinta before passing their recommendations to the Food and Drug Administration (FDA), which is aiming to decide in September whether or not the heart drug should be given marketing approval.
via telegraph.co.uk
Brilinta will face tough questions during a day-long meeting of medical experts and any news from the meeting could eclipse AstraZeneca's second-quarter results on Thursday. Among a small number of North American patients on Brilinta plus asprin, there was a non-significant trend towards a worse outcome.
No comments:
Post a Comment